IL10 and experimental autoimmune encephalomyelitis: Accumulating evidence indicates that combination therapy of MSCs and IL10 protein could have synergistic effects to reduce inflammation in various diseases such as experimental autoimmune encephalomyelitis [58], ischemia–reperfusion injury in the lung [59], and ischemic stroke [60, 61].